Naimish Patel
YOU?
Author Swipe
View article: A humanized mouse model system mimics prenatal Zika infection and reveals premature differentiation of neural stem cells
A humanized mouse model system mimics prenatal Zika infection and reveals premature differentiation of neural stem cells Open
View article: A humanized mouse model system mimics prenatal Zika infection and reveals premature differentiation of neural stem cells
A humanized mouse model system mimics prenatal Zika infection and reveals premature differentiation of neural stem cells Open
Zika, a mosquito-borne flavivirus, has been found in 87 countries and territories. Global outbreaks peaked in 2016. Prenatal infection of Zika virus was found to be associated with microcephaly, arthrogryposis, intracranial calcifications,…
View article: Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open‐Label, Phase <scp>II</scp> Study
Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open‐Label, Phase <span>II</span> Study Open
Background Peanut allergy is a potentially life‐threatening food allergy in children. This study explored whether dupilumab, a human monoclonal immunoglobulin (Ig)G4 antibody that blocks the activity of interleukin (IL)‐4/IL‐13, improved s…
View article: Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials Open
View article: Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study
Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study Open
Background Targeting receptor-interacting serine/threonine protein kinase 1 could mitigate the devastating sequelae of the hyperinflammatory state observed in severe cases of COVID-19. This study explored the immunomodulatory and clinical …
View article: Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial Open
Dupilumab monotherapy resulted in significant improvements across different domains of H/F AD with acceptable safety, supporting dupilumab as a systemic treatment approach for this often difficult to treat condition.
View article: Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials Open
Prurigo nodularis (PN) is a chronic inflammatory skin disease with intensely pruritic nodules. The LIBERTY-PN PRIME and PRIME2 phase 3 trials enrolled adults with PN with ≥20 nodules and severe itch uncontrolled with topical therapies. Dup…
View article: Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies
Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies Open
In a population of patients with CRSwNP and clinical features of obstructive lung disease, dupilumab improved CRSwNP and HRQoL outcomes, and, among those with a history of asthma, also improved lung function. These results support further …
View article: Response
Response Open
View article: AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis
AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis Open
AZD5634 showed favorable pharmacokinetics and safety in healthy subjects and patients with CF. However, despite achieving target engagement, proof of mechanism was not achieved after a single dose in patients with CF. Further evaluation in…
View article: Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps
Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps Open
View article: Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases Open
Background Type 2 inflammation is common in numerous atopic/allergic diseases and can be identified by elevated biomarker levels. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin‐4 and inte…
View article: Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP
Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP Open
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease with a high symptom burden and poor quality of life. Treatment options include recurrent surgeries and/or frequent systemic corticosteroids (SCS…
View article: Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial Open
View article: Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial
Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial Open
Summary Background Elevated proinflammatory cytokines have been associated with 2019 coronavirus disease (COVID-19) severity. We assessed efficacy and safety of sarilumab, an interleukin-6 receptor inhibitor, in severe (requiring supplemen…
View article: Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma Open
View article: Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma Open
View article: <p>Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function</p>
Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function Open
Dupilumab reduced severe exacerbations and improved lung function, asthma control and quality of life in patients with elevated baseline eosinophils irrespective of baseline ICS dose or FEV1% predicted.
View article: Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study
Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study Open
These safety and efficacy results support the use of dupilumab as a continuous long-term treatment for children aged ≥ 6 to < 12 years with severe AD.
View article: Dupilumab Improves Upper and Lower Airway Outcome Measures in Patients With CRSwNP With NSAID-ERD: Pooled Results from the SINUS-24 and SINUS-52 Phase 3 Trials
Dupilumab Improves Upper and Lower Airway Outcome Measures in Patients With CRSwNP With NSAID-ERD: Pooled Results from the SINUS-24 and SINUS-52 Phase 3 Trials Open
View article: Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial Open
Dupilumab + TCS is efficacious and well tolerated in children with severe AD, significantly improving signs, symptoms, and QOL.
View article: Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis Open
View article: Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study
Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study Open
In this subanalysis of QUEST, the efficacy and safety of dupilumab in Japanese patients was comparable to that observed in the overall intention-to-treat population, suggesting no variability in efficacy on the basis of Japanese ethnicity.…
View article: Table of contents
Table of contents Open
View article: Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS Open
View article: Baseline FeNO as a Prognostic Biomarker for Subsequent Severe Asthma Exacerbations in Patients With Uncontrolled, Moderate-to-Severe Asthma Receiving Placebo in the LIBERTY ASTHMA QUEST Study
Baseline FeNO as a Prognostic Biomarker for Subsequent Severe Asthma Exacerbations in Patients With Uncontrolled, Moderate-to-Severe Asthma Receiving Placebo in the LIBERTY ASTHMA QUEST Study Open
View article: Dupilumab Efficacy in GINA-Defined Difficult-to-Treat Type 2 Asthma Patients
Dupilumab Efficacy in GINA-Defined Difficult-to-Treat Type 2 Asthma Patients Open
View article: The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial
The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial Open
Although p38α is upregulated in the lungs of COPD patients, AZD7624, an isoform-specific inhaled p38 MAPK inhibitor, failed to show any benefit in patients with COPD.
View article: A Prospective Study of Anemia Profile of Chronic Liver Diseases Patients
A Prospective Study of Anemia Profile of Chronic Liver Diseases Patients Open
The present prospective study was conducted to evaluate the prevalence of anemia, its type and therapeutic measures in chronic liver disease (CLD) patients.In cross sectional study of anemia profile including, Complete Blood Count (CBC), r…
View article: WS13.2 Novel F508del-CFTR corrector that complements other CFTR modulators
WS13.2 Novel F508del-CFTR corrector that complements other CFTR modulators Open